Literature DB >> 6830028

Increased ventilation caused by improved diaphragmatic efficiency during aminophylline infusion.

M Aubier, D Murciano, N Viires, Y Lecocguic, S Palacios, R Pariente.   

Abstract

The mechanism underlying the increase in ventilation (VE) observed during aminophylline infusion was investigated in 12 anesthetized spontaneously breathing dogs. Progressive doses of aminophylline were infused every 30 min, leading to plasmatic levels of 10 to 20, 20 to 30, 30 to 50 mg/L. The increase in VE observed while increasing aminophylline plasmatic concentration ranged from 4.2 +/- 6 to 9.5 +/- 1.2 L/min. Concomitantly to VE, we measured an index of the inspiratory neuromuscular output of the diaphragm, the transdiaphragmatic pressure generated at FRC 0.1 s after the onset of a spontaneous inspiration developed against closed airways (Pdi0.1). For each plasmatic level of aminophylline, Pdi0.1 increased as VE (117 +/- 4, 126 +/- 2, 140 +/- 6% of control values for 10 to 20, 20 to 30, 30 to 50 mg/L, respectively). To establish the role played by an improvement in diaphragmatic contractility in the increase in Pdi0.1 with aminophylline, we measured for each plasmatic level of aminophylline the transdiaphragmatic pressure generated at FRC against closed airways during supramaximal stimulation at 10, 20, 50, and 100 Hz of the 2 phrenic nerves (Pdi). Pdi increased while increasing aminophylline plasmatic level for all the frequencies of stimulation. A relationship was found between Pdi and Pdi0.1 at any aminophylline plasmatic level as well as with VE. No change in the mechanical properties of the respiratory system occurred with aminophylline. We conclude that the increase in VE observed after aminophylline administration in our animal model is essentially due to an improvement in diaphragmatic contractility rather than an increase in the central nervous system output.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6830028     DOI: 10.1164/arrd.1983.127.2.148

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

Review 1.  Asthmatic drugs and competitive sport. An update.

Authors:  A R Morton; K D Fitch
Journal:  Sports Med       Date:  1992-10       Impact factor: 11.136

2.  Pathogenesis of respiratory failure in neuromuscular diseases: diagnosis and treatment.

Authors:  A Lissoni; F Molteni
Journal:  Ital J Neurol Sci       Date:  1986-10

3.  Effect of theophylline on respiratory neuromuscular drive.

Authors:  S Okubo; K Konno; T Ishizaki; M Kubo; T Suganuma; T Takizawa
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Lung function, hypoxic and hypercapnic ventilatory responses, and respiratory muscle strength in normal subjects taking oral theophylline.

Authors:  S Javaheri; L Guerra
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

Review 5.  Recovery of respiratory activity after C2 hemisection (C2HS): involvement of adenosinergic mechanisms.

Authors:  Kwaku D Nantwi
Journal:  Respir Physiol Neurobiol       Date:  2009-08-03       Impact factor: 1.931

Review 6.  Oral theophylline for chronic obstructive pulmonary disease.

Authors:  F S Ram; P W Jones; A A Castro; J A De Brito; A N Atallah; Y Lacasse; R Mazzini; R Goldstein; S Cendon
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  The use of anti-asthmatic drugs. Do they affect sports performance?

Authors:  K D Fitch
Journal:  Sports Med       Date:  1986 Mar-Apr       Impact factor: 11.136

8.  Effects of aminophylline on respiratory drive and neuromuscular coupling in normal man and in patients with chronic airflow obstruction.

Authors:  F Gigliotti; A Spinelli; C Lo Conte; R Duranti; M Gorini; G Scano
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  New avenues for reducing intensive care needs in patients with chronic spinal cord injury.

Authors:  Pierre A Guertin
Journal:  World J Crit Care Med       Date:  2016-11-04

10.  Pharmacokinetics of a 503B outsourcing facility-produced theophylline in dogs.

Authors:  Jennifer M Reinhart; Gabriela A R de Oliveira; Lauren Forsythe; Zhong Li
Journal:  PLoS One       Date:  2022-01-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.